HOTH News and Press, Hoth Therapeutics Inc. From 12/30/22

Palm Beach, FL – December 30, 2022 – FinancialNewsMedia.com News Commentary – According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. The global rheumatoid arthritis drugs market is ...

Nano-cap biotech Hoth Therapeutics ( NASDAQ: HOTH ) lost ~38% to end a two-day rally in the pre-market Friday after announcing a private placement to sell 2.0M shares of its common stock and warrants to raise $10M in gross proceeds. The capital raise is part of an agreement the co...

Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has...

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy PR Newswire On-track to initiate Phase 2 trial in Q1 2023 NEW YORK , Dec. ...

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 PR Newswire Clinical trial to begin early 2023 for Cancer patients NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused ...

Hoth Therapeutics ( NASDAQ: HOTH ) has regained compliance with Nasdaq's minimum bid price listing requirement. On Dec. 30, 2021, Nasdaq notified the company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business day...

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it receiv...

Clinical-stage biopharmaceutical company Hoth Therapeutics ( NASDAQ: HOTH ) announced Monday that its investigational therapy BioLexa met the primary and secondary endpoints for safety and efficacy in a Phase 1b trial for adults with mild-to-moderate atopic dermatitis (AD). ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Hoth Therapeutics (NASDAQ: HOTH ) stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa . BioLexa is a treatment in development at ...

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS PR Newswire MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACY BIOLEXA led to significant improvement in disease severity as measured by SCOR...